Kamada Ltd
NASDAQ:KMDA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
J
|
Job Solution Sweden Holding AB (publ)
STO:JOBS
|
SE |
Kamada Ltd
Free Cash Flow
Kamada Ltd
Free Cash Flow Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Free Cash Flow | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Kamada Ltd
NASDAQ:KMDA
|
Free Cash Flow
$15.6m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
|
Enlivex Therapeutics Ltd
NASDAQ:ENLV
|
Free Cash Flow
-$10.5m
|
CAGR 3-Years
31%
|
CAGR 5-Years
3%
|
CAGR 10-Years
2%
|
|
|
Urogen Pharma Ltd
NASDAQ:URGN
|
Free Cash Flow
-$162.7m
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
N/A
|
|
|
Entera Bio Ltd
NASDAQ:ENTX
|
Free Cash Flow
-$7.5m
|
CAGR 3-Years
16%
|
CAGR 5-Years
7%
|
CAGR 10-Years
N/A
|
|
|
Pluri Inc
NASDAQ:PLUR
|
Free Cash Flow
-$22m
|
CAGR 3-Years
12%
|
CAGR 5-Years
4%
|
CAGR 10-Years
-1%
|
|
|
M
|
Matricelf Ltd
TASE:MTLF
|
Free Cash Flow
-₪12m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Kamada Ltd
Glance View
Kamada Ltd. engages in the development and production of pharmaceutical products. The firm uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins.
See Also
What is Kamada Ltd's Free Cash Flow?
Free Cash Flow
15.6m
USD
Based on the financial report for Dec 31, 2025, Kamada Ltd's Free Cash Flow amounts to 15.6m USD.
What is Kamada Ltd's Free Cash Flow growth rate?
Free Cash Flow CAGR 5Y
3%
Over the last year, the Free Cash Flow growth was -58%. The average annual Free Cash Flow growth rates for Kamada Ltd have been -14% over the past three years , 3% over the past five years .
